VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

A. Your doctor was correct that depression and suicidal thoughts do not appear in the official prescribing information for evolocumab (Repatha) or a similar drug, alirocumab (Praluent). Both are ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...

Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolucumab). This follows ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced ...